会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • Recombinant glycoproteins, method for the production thereof, medicaments containing said glycoproteins and use thereof
    • 重组糖蛋白,其生产方法,含有所述糖蛋白的药物及其用途
    • US06692931B1
    • 2004-02-17
    • US09831868
    • 2001-12-13
    • Werner ReutterRudolf TauberRüdiger HorstkorteSabine NöhringMartin GohlkeRolf NuckRichard R. SchmidtCharlotte Hauser
    • Werner ReutterRudolf TauberRüdiger HorstkorteSabine NöhringMartin GohlkeRolf NuckRichard R. SchmidtCharlotte Hauser
    • C12Q156
    • C07K14/47A61K38/00C07K14/505
    • The invention relates to novel recombinant glycoproteins that act as messenger substances, signaling substances, promoters, stimulators and initiators in a multitude of ways in the animal, especially human, circulation system. The invention also relates to a method for the production thereof, pharmaceutical agents containing said glycoproteins and the use thereof The invention more particularly relates to novel recombinant human glycoproteins (rh glycoproteins), preferably novel rh differentiation factors, especially rh erythropoietin; novel rh growth factors, especially rh CSF (colony stimulating factor), rh GMCSF (granulocytes monocytes stimulation factor); novel rh thrombolytic agents, especially rh tPA (tissue plasminogen activator) and rh urokinase; novel rh thromboprophylactic agents, especially rh antithrombin III; novel rh coagulation factors, especially rh factor VIII and rh factor IX; novel rh interferons, especially rh &agr;, &bgr; and &ggr; interferons; and novel rh interleukins, especially rh IL-2, IL-15, IL-16 and IL-17. The invention further relates to a method for the production of said substances, pharmaceutical agents containing them and to the use thereof.
    • 本发明涉及在动物,特别是人类循环系统中以多种方式用作信使物质,信号物质,促进剂,刺激剂和引发剂的新型重组糖蛋白。 本发明还涉及其生产方法,含有所述糖蛋白的药物及其用途。本发明更具体涉及新型重组人糖蛋白(rh糖蛋白),优选新颖的rh分化因子,特别是促红细胞生成素; rh细胞生长因子,特别是rh CSF(集落刺激因子),rhGMCSF(粒细胞单核细胞刺激因子); 新型rh溶栓剂,特别是rh tPA(组织纤溶酶原激活物)和rh尿激酶; 新型rh血栓预防剂,特别是rh抗凝血酶III; 新型rh凝血因子,特别是rh因子VIII和rh因子IX; 新型rh干扰素,特别是rhα,β和γ干扰素; 和新型rh白介素,特别是rh IL-2,IL-15,IL-16和IL-17。 本发明还涉及生产所述物质的方法,含有它们的药剂及其用途。
    • 5. 发明授权
    • Process for the preparation of sphingosine derivatives
    • 鞘氨醇衍生物的制备方法
    • US4952683A
    • 1990-08-28
    • US137957
    • 1987-12-24
    • Roland TschannenWolfgang FraefelRichard R. SchmidtRudolf KlagerPeter Zimmermann
    • Roland TschannenWolfgang FraefelRichard R. SchmidtRudolf KlagerPeter Zimmermann
    • A61K31/70C07H15/10
    • C07H15/10Y02P20/55
    • New compounds of the formula (I)-D and (I)-L as shown in the sheet of formulae are described, for example D- and L-erythro-1-(.beta.-D-glycopyranosyloxy)-3-hydroxy-2-palmitoylamino-4-trans-octadecene, which exert actions promoting wound healing and cell and tissue regeneration, and can be used therapeutically for the treatment of wounds of any cause. They are prepared in good yield and in a stereochemically homogeneous form from ceramides of the formula (II)-D and/or (II)-L. The process comprises the protection of the 1-hydroxyl group, esterification of the 3-hydroxyl group, elimination of the 1-hydroxyl protective group, reaction with the trifluoroacetimidate or trichloroacetimidate of a 2,3,4,6-tetraacylated D-glucose and elimination of the O-acyl groups. When a D,L-ceramide (II) is used, the esterification of the 3-hydroxyl group is carried out by an optically active acid followed by separation into the diastereomers, or separation into the diastereomers is carried out after the reaction with the D-glucose derivative.
    • 描述了式(I)-D和(I)-L的新化合物,如式中所示,例如D-和L-赤式-1-(β-D-糖吡喃糖基氧基)-3-羟基-2 - 棕榈酰氨基-4-反式十八碳烯,其发挥促进伤口愈合和细胞和组织再生的作用,并且可以用于治疗任何原因的伤口。 它们以良好的收率和立体化学均匀的形式由式(II)-D和/或(II)-L的神经酰胺制备。 该方法包括1-羟基的保护,3-羟基的酯化,1-羟基保护基的消除,与3,4,4,6-四酰化D-葡萄糖的三氟乙酰亚胺酸酯或三氯乙酰亚胺酸酯的反应,以及 消除O-酰基。 当使用D,L-神经酰胺(II)时,3-羟基的酯化通过光学活性酸进行,然后分离成非对映异构体,或者在与D反应后进行非对映异构体的分离 - 葡萄糖衍生物。
    • 8. 发明授权
    • Preparation of alkyl
(6R,7S,8R)-6,9-dihydroxy-7,8-isopropylidenedioxy-2,4-nonadienoates and
their use for the preparation of D-biotin
    • (6R,7S,8R)-6,9-二羟基-7,8-异亚丙基二氧基-2,4-非二烯酸的制备及其用于制备D-生物素
    • US4777273A
    • 1988-10-11
    • US899792
    • 1986-08-25
    • Richard R. SchmidtMartin Maier
    • Richard R. SchmidtMartin Maier
    • C07D317/30
    • C07D317/30
    • Alkyl (6R,7S,8R)-6,9-dihydroxy-7,8-isopropylidenedioxy-2,4-nonadienoates of the formula I ##STR1## where R is alkyl of 1 to 4 carbon atoms are prepared by reacting 3,5-O-isopropylidene-D-arabinose of the formula II ##STR2## with a 3-carboalkoxyprop-2-en-1-ylidene triphenylphosphorane of the formula III ##STR3## in a solvent at elevated temperatures, by a process wherein the reaction is carried out in, as the solvent, a suitable aliphatic or aromatic hydrocarbon, a halogen derivative thereof or a cycloaliphatic ether, preferably an aromatic hydrocarbon of 6 to 8 carbon atoms, at from 65 to 130.degree. C., preferably from 80 to 115.degree. C.Using this process, the basic skeleton of d-biotin can be synthesized from D-arabinose in substantially better yields than obtainable hitherto.
    • 通式I(I)的烷基(6R,7S,8R)-6,9-二羟基-7,8-异亚丙基二氧基-2,4-非二烯酸酯其中R是1至4个碳原子的烷基是通过使 式(II)的3,5-二异丙基-D-阿拉伯糖与式III的3-碳烷氧基-2-丙烯-1-基三苯基正膦(III)在升高的溶剂中反应 温度,其中反应在溶剂中进行,其中反应在65-130℃下作为溶剂进行合适的脂族或芳族烃,其卤素衍生物或脂环族醚,优选6至8个碳原子的芳族烃。 优选为80-115℃。使用该方法,可以从D-阿拉伯糖合成D-生物素的基本骨架,其产率远高于迄今所得的产率。